Showing results (161-170 of 1,598) with videos related to
Sort By:
Pageof 160
Cancer Journal (Sudbury, Mass.)|October 15, 2009
Other paradigms: randomized discontinuation trial designWalter StadlerCancer Journal (Sudbury, Mass.)|October 15, 2009
Other paradigms: growth rate constants and tumor burden determined using computed tomography data correlate strongly with the overall survival of patients with renal cell carcinomaWilfred D Stein, Hui Huang, Michael Menefee, et al.Cancer Journal (Sudbury, Mass.)|April 15, 2017
Identifying Abundant Immunotherapy and Other Targets in Solid Tumors: Integrating RNA-seq and Mass Spectrometry Proteomics Data SetsWei Zhao, Matthew Fitzgibbon, Lindsay Bergan, et al.Cancer Journal (Sudbury, Mass.)|April 15, 2017
Tumor-Infiltrating Lymphocyte Therapy and NeoantigensPaul F RobbinsCancer Journal (Sudbury, Mass.)|June 10, 2008
An update on the treatment of CNS metastases in small cell lung cancerWilliam A Castrucci, Jonathan P S KniselyCancer Journal (Sudbury, Mass.)|June 10, 2008
Antibodies for molecular imaging of cancerAnna M Wu, Tove OlafsenCancer Journal (Sudbury, Mass.)|June 10, 2008
Adjuvant concurrent chemoradiotherapy with intensity-modulated pelvic radiotherapy after surgery for high-risk, early stage cervical cancer patientsMiao-Fen Chen, Chih-Jen Tseng, Ching-Cheng Tseng, et al.Cancer Journal (Sudbury, Mass.)|June 8, 2015
Prevalence of Human Papillomavirus in Oropharyngeal Cancer: A Systematic ReviewAndrew P Stein, Sandeep Saha, Jennifer L Kraninger, et al.Cancer Journal (Sudbury, Mass.)|June 8, 2015
Image-Guided Tumor ResectionJulia Parrish-Novak, Eric C Holland, James M OlsonCancer Journal (Sudbury, Mass.)|June 8, 2015
How Imaging Can Impact Clinical Trial Design: Molecular Imaging as a Biomarker for Targeted Cancer TherapyDavid A Mankoff, Michael D Farwell, Amy S Clark, et al.Pageof 160